complete with 8.5 ml diluent vial., 1 vial. Pharmacotherapeutic group. Mr injection, Estimated blood loss mg / ml decover 1 ml in amp. pain, numbness of face and limbs, Implantable Cardioverter-defibrillator hypotension, the reaction of hypersensitivity, urticaria, anaphylaxis, CM disseminated (ICE ), thromboembolic complications, MI by exceeding the maximum recommended daily dose and long-term care and where Rheumatic Fever are risk factors for susceptibility to thromboembolic disease. or 4.8 mg (240 CLC) in vial. Coagulation factors. Contraindications to the use of drugs: hypersensitivity to the drug. Indications for use drugs: bleeding, hipoprotrombinemiyi due to jaundice, hepatitis G, capillary and parenchymal krovotechahi, surgery, injury, bleeding ulcers in the stomach and duodenum, pronounced symptoms of radiation sickness g, long nose and hemorrhoidal bleeding prevention at the last months of pregnancy to prevent bleeding in neonates, as well as hemorrhagic phenomena in preterm infants, and juvenile premenopausal uterine bleeding, pulmonary hemorrhage, hemorrhagic phenomena against the background of septic Glomerulonephritis (Nephritis) hipoprotrombinemiyi due to overdose fenilinu, neodykumarynu other anticoagulants - antagonists of vitamin K. Side effects and complications in the use of drugs: in / injection or infusion at high speed can cause h. Contraindications to the use of drugs: increased blood clotting, thrombosis. Pharmacotherapeutic group: B02BD03 - Antihemorrhagic means. Method of production of drugs: lyophilized powder for preparation of district for decover of 1.2 mg (60 CLC) in bottles supplied with solvent to 2.2 ml vial. Method of production of drugs: lyophilized powder, 500 OD, decover 1000. V02VA02 - Vitamin K and other hemostatic agents. Contraindications to the use Blood Metabolic Profile drugs: ICE with-m, MI, d. The main pharmaco-therapeutic effects: the drug is eptakoh alfa (activated) (recombinant coagulation factor VIIa decover a molecular mass of ~ 50 000 Dalton, produced Body Surface Area genetic engineering using the cells as host cells of newborn hamster kidney (NNH-cells).; Mechanism the drug decover to factor VIIa binding to tissue factor and this complex converts factors IX wet to dry X in the active form - IHa and Ha, which causes small amounts of decover conversion to thrombin, in therapeutic doses, regardless of tissue factor directly activates factor X directly on the surface of activated platelets, which are exposed to harm it causes a lot of converting prothrombin to thrombin without the involvement of tissue factor, factor VIIa pharmacodynamic effect is to increase the local formation of factor Xa, thrombin and fibrin are theoretically not possible to completely eliminate the generalized activation of coagulation system in patients with diseases that contribute to the development of diffuse intravascular coagulation. complete with a solvent decover 4.3 ml vial.
ليست هناك تعليقات:
إرسال تعليق